NCT00022659View on ClinicalTrials.gov

Bevacizumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

April 30, 2002

Primary Completion Date

March 31, 2010

Study Completion Date

March 31, 2010

Conditions
Primary Peritoneal Cavity CancerRecurrent Ovarian Epithelial CancerStage IV Ovarian Epithelial Cancer
Interventions
BIOLOGICAL

bevacizumab

Given IV

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

19103

Gynecologic Oncology Group, Philadelphia

All Listed Sponsors
collaborator

Gynecologic Oncology Group

NETWORK

lead

National Cancer Institute (NCI)

NIH

NCT00022659 - Bevacizumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer | Biotech Hunter | Biotech Hunter